The "affordable growth" approach sits in a specific part of the market where a company demonstrates a strong expansion trajectory without demanding the premium valuation multiples often attached to high-growth names. The idea is to capture the upside of earnings acceleration while reducing some of the valuation risk that comes with it. It requires balancing several fundamental factors: growth must be solid, valuation should stay within reason, and the business needs to show that its profitability and financial health can support that expansion. One stock that currently fits this profile is LivaNova Plc (NASDAQ:LIVN).
Growth: Consistent Expansion Across Past and Future
The growth profile is the primary entry point for this strategy. LivaNova scores a 7 out of 10 on ChartMill’s Growth Rating, indicating a solid record and a promising outlook.
Looking at the past performance, the numbers speak clearly:
- Earnings per share (EPS) grew by 13.64% over the last year.
- Over a multi-year period, EPS has compounded at an impressive 25.16% annually.
- Revenue growth has been steadier, rising 12.39% over the past year and averaging 8.24% per year over the longer term.
Crucially for an affordable growth thesis, the forward estimates do not suggest a cliff. Analysts expect EPS to continue growing at an average rate of 18.62% per year over the next few years, while revenue is projected to expand by roughly 8.64% annually. Growth is expected to slow slightly from the past highs, but the path remains far above the average company, justifying the classification as a growth stock. Stable revenue growth combined with solid EPS expansion is exactly the pattern that can support a reasonable valuation over time.
Valuation: Relative Bargain Within the Industry
Valuation is the second pillar of this strategy, and on this front, LivaNova presents a nuanced case. The company holds a Valuation Rating of 5 out of 10.
On an absolute basis, the stock is not "cheap." The trailing Price/Earnings (P/E) ratio sits at 19.80, which is above the broader market average. However, context is critical. LivaNova operates within the Health Care Equipment & Supplies industry, which is notoriously expensive. When compared against its 188 industry peers, the story changes dramatically:
- LivaNova is cheaper than 81.38% of its industry peers based on the trailing P/E ratio.
- The Price/Forward Earnings ratio of 16.95 is lower than 79.26% of the industry.
- On Enterprise Value to EBITDA and Price/Free Cash Flow multiples, 79.79% of industry peers are more expensive.
These relative figures are essential. A stock can appear expensive in isolation but be a relative value play within its sector. This gap is precisely what the affordable growth screen captures. Furthermore, the PEG ratio, which adjusts the P/E for the expected growth rate, indicates a fair valuation. When a company grows EPS at nearly 20% annually while trading below the average industry multiple, it creates the kind of asymmetry that value-conscious growth investors look for. You can review all the underlying metrics in the detailed fundamental analysis report for LivaNova.
Profitability: Efficient Operations in the Top Tier
A growth story is only convincing if the business is actually making money. LivaNova scores a strong 7 out of 10 for Profitability.
The efficiency metrics stand out against the competition:
- Return on Assets (ROA) of 4.26% outperforms 79.26% of the industry.
- Return on Equity (ROE) of 8.85% beats 80.32% of peers.
- Return on Invested Capital (ROIC) of 8.01% is among the best in the industry, outperforming 85.64% of competitors.
Margins also tell a positive story. The Profit Margin of 7.47% and the Operating Margin of 13.68% both rank in the top 20% of the industry. Notably, the operating margin has improved in recent years, and the latest ROIC figure of 8.01% is well above the three-year average of 5.19%, indicating that profitability is on an upward trend. This is a key factor for the affordable growth strategy: growing profits signal that the company is not just expanding for its own sake, but is doing so efficiently.
Health: Solid Solvency with Liquidity Concerns
Financial health is the final check, and here the picture is mixed. LivaNova scores a 5 out of 10.
The solvency side is reassuring. The company has a Debt/Equity ratio of just 0.24, meaning it relies very little on debt financing. The Debt to Free Cash Flow ratio is a strong 1.79, implying the company could theoretically pay off all its debt in less than two years using its free cash flow. This is a very positive signal for financial stability.
The concern lies in liquidity. The Current Ratio of 1.33 and the Quick Ratio of 1.11 are adequate but notably weaker than industry averages, placing LivaNova in the lower quartile of its peer group. For the affordable growth strategy, the health rating acts as a filter to avoid overleveraged stories. While LivaNova has room to improve its short-term liquidity, its solvency is sound, and it passes the threshold required to remain in this screen. The business is not taking excessive financial risk to chase growth.
Summary: The Screen in Action
LivaNova checks the key boxes for an affordable growth candidate: a strong and sustainable growth trajectory, a valuation that is reasonable relative to its industry, top-tier profitability, and adequate financial health. This combination is difficult to find, especially in the expensive Health Care Equipment sector.
To see which other stocks are currently passing the same affordable growth criteria, you can run the full affordable growth stock screen to explore more names that fit this specific profile.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always perform your own due diligence or consult with a qualified financial professional before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
LivaNova (NASDAQ:LIVN) Fits the Affordable Growth Profile with Strong Earnings and Relative Value
The "affordable growth" approach sits in a specific part of the market where a company demonstrates a strong expansion trajectory without demanding the premium valuation multiples often attached to high-growth names. The idea is to capture the upside of earnings acceleration while reducing some of the valuation risk that comes with it. It requires balancing several fundamental factors: growth must be solid, valuation should stay within reason, and the business needs to show that its profitability and financial health can support that expansion. One stock that currently fits this profile is LivaNova Plc (NASDAQ:LIVN).
Growth: Consistent Expansion Across Past and Future
The growth profile is the primary entry point for this strategy. LivaNova scores a 7 out of 10 on ChartMill’s Growth Rating, indicating a solid record and a promising outlook.
Looking at the past performance, the numbers speak clearly:
Crucially for an affordable growth thesis, the forward estimates do not suggest a cliff. Analysts expect EPS to continue growing at an average rate of 18.62% per year over the next few years, while revenue is projected to expand by roughly 8.64% annually. Growth is expected to slow slightly from the past highs, but the path remains far above the average company, justifying the classification as a growth stock. Stable revenue growth combined with solid EPS expansion is exactly the pattern that can support a reasonable valuation over time.
Valuation: Relative Bargain Within the Industry
Valuation is the second pillar of this strategy, and on this front, LivaNova presents a nuanced case. The company holds a Valuation Rating of 5 out of 10.
On an absolute basis, the stock is not "cheap." The trailing Price/Earnings (P/E) ratio sits at 19.80, which is above the broader market average. However, context is critical. LivaNova operates within the Health Care Equipment & Supplies industry, which is notoriously expensive. When compared against its 188 industry peers, the story changes dramatically:
These relative figures are essential. A stock can appear expensive in isolation but be a relative value play within its sector. This gap is precisely what the affordable growth screen captures. Furthermore, the PEG ratio, which adjusts the P/E for the expected growth rate, indicates a fair valuation. When a company grows EPS at nearly 20% annually while trading below the average industry multiple, it creates the kind of asymmetry that value-conscious growth investors look for. You can review all the underlying metrics in the detailed fundamental analysis report for LivaNova.
Profitability: Efficient Operations in the Top Tier
A growth story is only convincing if the business is actually making money. LivaNova scores a strong 7 out of 10 for Profitability.
The efficiency metrics stand out against the competition:
Margins also tell a positive story. The Profit Margin of 7.47% and the Operating Margin of 13.68% both rank in the top 20% of the industry. Notably, the operating margin has improved in recent years, and the latest ROIC figure of 8.01% is well above the three-year average of 5.19%, indicating that profitability is on an upward trend. This is a key factor for the affordable growth strategy: growing profits signal that the company is not just expanding for its own sake, but is doing so efficiently.
Health: Solid Solvency with Liquidity Concerns
Financial health is the final check, and here the picture is mixed. LivaNova scores a 5 out of 10.
The solvency side is reassuring. The company has a Debt/Equity ratio of just 0.24, meaning it relies very little on debt financing. The Debt to Free Cash Flow ratio is a strong 1.79, implying the company could theoretically pay off all its debt in less than two years using its free cash flow. This is a very positive signal for financial stability.
The concern lies in liquidity. The Current Ratio of 1.33 and the Quick Ratio of 1.11 are adequate but notably weaker than industry averages, placing LivaNova in the lower quartile of its peer group. For the affordable growth strategy, the health rating acts as a filter to avoid overleveraged stories. While LivaNova has room to improve its short-term liquidity, its solvency is sound, and it passes the threshold required to remain in this screen. The business is not taking excessive financial risk to chase growth.
Summary: The Screen in Action
LivaNova checks the key boxes for an affordable growth candidate: a strong and sustainable growth trajectory, a valuation that is reasonable relative to its industry, top-tier profitability, and adequate financial health. This combination is difficult to find, especially in the expensive Health Care Equipment sector.
To see which other stocks are currently passing the same affordable growth criteria, you can run the full affordable growth stock screen to explore more names that fit this specific profile.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always perform your own due diligence or consult with a qualified financial professional before making investment decisions.
Read full article here »